StockNews.AI
STTK
StockNews.AI
48 days

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

1. Shattuck Labs participates in an upcoming therapeutics forum on July 8–9, 2025. 2. CEO to discuss SL-325, a potential first-in-class DR3 blocker for IBD. 3. Preclinical studies show SL-325's superior activity compared to current antibodies. 4. IND filing for SL-325 expected in Q3 2025, following successful toxicology study. 5. Development of SL-325 may position Shattuck as a leader in IBD treatment.

4m saved
Insight
Article

FAQ

Why Bullish?

The announcement of an IND filing and participation in conferences often leads to stock price increases in biotech firms, especially when associated with promising treatments. Historical trends show biotech stocks often rise upon pending FDA filings or scientific discussions indicating progress.

How important is it?

The article highlights critical advancements and timelines in drug development, which significantly impact investor sentiment and expectations for STTK’s future performance.

Why Long Term?

While immediate impact may occur post-conference, the long-term trajectory is dependent on SL-325's clinical trial success and eventual market release, similar to past biotech successes where investor confidence builds over time with strategic developments.

Related Companies

IBDTL1A
July 02, 2025 07:00 ET  | Source: Shattuck Labs, Inc. AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8–9, 2025 in Boston, MA. Conference DetailsFormat: Panel Discussion and one-on-one meetingsSession Title: TL1A: Pioneering a New MOA in IBD and Beyond Moderators: Thomas J. Smith, Analyst, Leerink & Faisal A. Khurshid, Analyst, LeerinkPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: July 8, 2025Time: 4:15-5:00 PM ETLocation: Boston Harbor Hotel, Boston, MA About SL-325SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 has completed a GLP toxicology study in non-human primates, with an IND filing expected in the third quarter of 2025. About Shattuck Labs, Inc.Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com

Related News